Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancer

doi:10.1016/j.bbcan.2024.189221

	Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancer
	Bi, Ruomeng 1; Chen, Li2 ; Huang, Mei2 ; Qiao, Zhi2 ; Li, Zhen 3; Fan, Gaofeng4 ; Wang, Yu 5
	2024-11-01
发表期刊	BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (IF:9.7[JCR-2023],11.2[5-Year])
ISSN	0304-419X
EISSN	1879-2561
卷号	1879 期号:6
发表状态	已发表
DOI	10.1016/j.bbcan.2024.189221
摘要	The utilization of PARP inhibitors (PARPis) has significantly improved the prognosis for ovarian cancer patients. However, as the use of PARPis increases, the issue of PARPi resistance has become more prominent. Prolonged usage of PARPis can lead to the development of resistance in ovarian cancer, often mediated by mechanisms such as homologous recombination (HR) recovery, ultimately resulting in cancer relapse. Overcoming PARPi resistance in ovarian cancer is a pressing concern, aiming to enhance the clinical benefits of PARPi treatment and delay disease recurrence. Here, we summarize the mechanisms underlying PARPi resistance, methods for analyzing resistance, and strategies for overcoming it. Our goal is to inspire the development of more costeffective and convenient methods for analyzing resistance mechanisms, as well as safer and more effective strategies to overcome resistance. These advancements can contribute to developing personalized approaches for treating ovarian cancer.
关键词	Ovarian cancer PARP inhibitor Resistance Combination therapy PROTAC
URL	查看原文
收录类别	SCI
语种	英语
资助项目	Ministry of Science and Technology of the People's Republic of China[2021YFA0804700] ; National Natural Science Foundation of China["32370764","82072866","82272888","82204047"] ; Shanghai Jiao Tong University[YG2022ZD005] ; Shanghai Hospital Development Center Foundation[SHDC12022106]
WOS研究方向	Biochemistry & Molecular Biology ; Biophysics ; Oncology
WOS类目	Biochemistry & Molecular Biology ; Biophysics ; Oncology
WOS记录号	WOS:001372728300001
出版者	ELSEVIER
引用统计	正在获取...
文献类型	期刊论文
条目标识符	https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/452329
专题	生命科学与技术学院_博士生生命科学与技术学院_PI研究组_范高峰组生命科学与技术学院_硕士生
共同第一作者	Chen, Li; Huang, Mei
通讯作者	Li, Zhen; Fan, Gaofeng; Wang, Yu
作者单位	1.Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai 200092, China. 2.School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China. 3.Clinical Research Unit, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai 200092, China. Electronic address: zhen_li@tongji.edu.cn. 4.School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China; Shanghai Clinical Research and Trial Center, Shanghai 201210, China. Electronic address: fangf@shanghaitech.edu.cn. 5.Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai 200092, China; Department of Gynecology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai 200092, China.
通讯作者单位	生命科学与技术学院
推荐引用方式 GB/T 7714	Bi, Ruomeng,Chen, Li,Huang, Mei,et al. Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancer[J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER,2024,1879(6).
APA	Bi, Ruomeng.,Chen, Li.,Huang, Mei.,Qiao, Zhi.,Li, Zhen.,...&Wang, Yu.(2024).Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancer.BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER,1879(6).
MLA	Bi, Ruomeng,et al."Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancer".BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER 1879.6(2024).